A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Rifaximin (Primary) ; Lactulose
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- 01 Mar 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.
- 18 Aug 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Dec 2016, as reported by ClinicalTrials.gov.
- 18 Aug 2015 Status changed from recruiting to not yet recruiting, as reported by ClinicalTrials.gov.